
Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.
Dr. Metz describes the inflammatory cell infiltrate seen in PN and CSU and how inflammatory cells in the skin contribute to a type 2 inflammatory environment.
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
In this video from EADV 2025, Professor Metz shares exciting data from therapies recently approved or in late-stage development for CSU.

Dr. Kim describes current understandings of neuroimmune interactions in PN and CSU, including the roles of neurogenic inflammation in each disease.
Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.

Presentation highlights from the ADVENT symposium on disease remission in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.

Presentation highlights from the ADVENT symposium on smell loss and nasal congestion in CRSwNP at the 42nd Congress of the International Society of Inflammation and Allergy of the Nose and 24th Congress of the International Rhinologic Society in Tokyo, Japan.

From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.

Join Dr. Hawkes as he discusses what burdens and challenges CSU patients might expect and help identify that there are immune functions responsible for their symptoms not an external cause.